In this retrospective, single institution series, authors analyzed the outcome of patients with primary caval leiomyosarcoma (LMS) treated from 2012 to 2018. They reported a similar survival outcome for patients with caval LMS compared to those with similar non-caval LMS. Furthermore, the authors performed an exploratory analysis of differential gene expression among patients with LMS.

Find full article here.